Humana (NYSE:HUM) Given New $350.00 Price Target at Citigroup

Humana (NYSE:HUM) had its price target increased by Citigroup from $340.00 to $350.00 in a report released on Thursday, Stock Target Advisor reports. They currently have a buy rating on the insurance provider’s stock.

Several other equities analysts have also recently commented on HUM. Deutsche Bank initiated coverage on shares of Humana in a research note on Thursday, September 12th. They set a hold rating and a $300.00 price objective for the company. BMO Capital Markets cut shares of Humana from an outperform rating to a market perform rating and reduced their price objective for the company from $345.00 to $290.00 in a research note on Monday, September 30th. ValuEngine raised shares of Humana from a hold rating to a buy rating in a research note on Friday. Cantor Fitzgerald raised shares of Humana from a neutral rating to an overweight rating and boosted their price target for the stock from $300.00 to $345.00 in a research note on Monday, August 12th. Finally, Mizuho began coverage on shares of Humana in a research note on Thursday, October 17th. They issued a buy rating and a $316.00 price target for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the company. Humana presently has a consensus rating of Buy and an average target price of $322.63.

NYSE:HUM traded up $2.44 during mid-day trading on Thursday, hitting $317.58. 1,173,375 shares of the stock traded hands, compared to its average volume of 1,220,728. The business’s 50-day moving average price is $277.48 and its 200 day moving average price is $270.93. The company has a market cap of $39.82 billion, a PE ratio of 21.83, a price-to-earnings-growth ratio of 1.27 and a beta of 0.85. Humana has a 12-month low of $225.65 and a 12-month high of $342.03. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.37.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, November 6th. The insurance provider reported $5.03 EPS for the quarter, beating the consensus estimate of $4.58 by $0.45. The company had revenue of $16.24 billion during the quarter, compared to analysts’ expectations of $16.15 billion. Humana had a net margin of 4.13% and a return on equity of 22.47%. Humana’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.58 earnings per share. Analysts anticipate that Humana will post 17.75 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a $0.55 dividend. The ex-dividend date of this dividend is Monday, December 30th. This represents a $2.20 dividend on an annualized basis and a yield of 0.69%. Humana’s dividend payout ratio is presently 15.12%.

In other Humana news, insider Brian P. Leclaire sold 7,239 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $289.70, for a total value of $2,097,138.30. Following the completion of the transaction, the insider now owns 12,994 shares of the company’s stock, valued at approximately $3,764,361.80. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.54% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Cornerstone Advisors Inc. lifted its holdings in shares of Humana by 9.9% in the 3rd quarter. Cornerstone Advisors Inc. now owns 388 shares of the insurance provider’s stock worth $99,000 after acquiring an additional 35 shares during the last quarter. Lindbrook Capital LLC lifted its holdings in shares of Humana by 12.0% in the 3rd quarter. Lindbrook Capital LLC now owns 327 shares of the insurance provider’s stock worth $84,000 after acquiring an additional 35 shares during the last quarter. Regentatlantic Capital LLC lifted its holdings in shares of Humana by 0.4% in the 2nd quarter. Regentatlantic Capital LLC now owns 9,617 shares of the insurance provider’s stock worth $2,551,000 after acquiring an additional 42 shares during the last quarter. Ballentine Partners LLC lifted its holdings in shares of Humana by 2.5% in the 3rd quarter. Ballentine Partners LLC now owns 1,751 shares of the insurance provider’s stock worth $448,000 after acquiring an additional 42 shares during the last quarter. Finally, Cim Investment Mangement Inc. lifted its holdings in shares of Humana by 4.3% in the 2nd quarter. Cim Investment Mangement Inc. now owns 1,125 shares of the insurance provider’s stock worth $298,000 after acquiring an additional 46 shares during the last quarter. 92.93% of the stock is owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Story: Conference Calls and Individual Investors

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.